Mylan posts third-quarter loss on proposed settlement costs

(Reuters) - Generic drugmaker Mylan NV, which is under investigation and has faced harsh criticism over steep price increases for its EpiPen emergency allergy treatment, on Wednesday reported a third quarter loss due the cost of a proposed settlement with the U.S. department of Justice and other government agencies.